# BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
Canonical URL: https://biopharmsignal.com/news/BCAB/bioatla-to-announce-second-quarter-2025-financial-results-and-provide-business-h-f0f645d9
Ticker: BCAB
Company: BioAtla, Inc.
Source: BioAtla, Inc.
Published: 2025-08-04 12:00 EST
## Summary

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

## Article Body
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights.

Conference Call and Webcast Information Date: Thursday, August 7, 2025 Time: 4:30 p.m. ET Webcast Link: BioAtla Second Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (international) Conference ID: BIOATLA

The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website. A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.

About BioAtla®, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com .

Internal Contact: Richard Waldron Chief Financial Officer BioAtla, Inc. rwaldron@bioatla.com 858.356.8945

External Contact: Joyce Allaire LifeSci Advisors, LLC jallaire@lifesciadvisors.com
## Recent Company News
- 2026-03-31 20:06 EST — [BioAtla Announces Share Consolidation](https://biopharmsignal.com/news/BCAB/bioatla-announces-share-consolidation-87cc80c0) — Source: BioAtla, Inc.
- 2026-03-31 20:05 EST — [BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/BCAB/bioatla-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-12e923ba) — Source: BioAtla, Inc.
- 2026-03-02 12:30 EST — [BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets](https://biopharmsignal.com/news/BCAB/bioatla-announces-formal-process-to-evaluate-strategic-options-to-monetize-asset-845454d9) — Source: BioAtla, Inc.
- 2025-12-31 12:00 EST — [BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)](https://biopharmsignal.com/news/BCAB/bioatla-and-gatc-health-announce-a-40-million-special-purpose-vehicle-spv-transa-3cc03299) — Source: BioAtla, Inc.
- 2025-11-21 05:25 EST — [BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing](https://biopharmsignal.com/news/BCAB/bioatla-enters-into-agreements-for-up-to-22-5-million-flexible-financing-33b8bcad) — Source: BioAtla, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)